Chong Kun Dang wins first overseas approval for phase 3 trial of COVID-19 treatment
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Drugmaker Chong Kun Dang said Thursday that it has received an approval from the Ministry of Health of Ukraine to conduct a phase 3 clinical trial of their COVID-19 treatment candidate, Nafabeltan.
Ukraine is the first foreign country to authorize the final-stage trial of the South Korean pharmaceutical company’s self-developed COVID-19 treatment.
In Korea, Chong Kun Dang received an approval from the Ministry of Food and Drug Safety in April.
Ukraine is one of the seven foreign countries that the firm is planning to run the test in, with the others being Brazil, India, Thailand, Russia, Argentina, and Peru.
Chong Kun Dang will evaluate efficacy and safety of Nafabeltan through double-blind studies with a total of 600 COVID-19 patients at high risk for progression to severe COVID-19 cases.
Nafabeltan inhibits the activity of the spike protein of COVID-19. The company expects the treatment candidate to be effective against the existing COVID-19 variants, including the delta and lambda variants.
By Shim Woo-hyun(ws@heraldcorp.com)
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.